Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
Description: BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The company?s products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death. Its HypoThermosol series of products include HypoThermosol FRS, a solution formulated to decrease the free radical accumulation in cells undergoing prolonged hypothermic preservation; and PrepaStor, a flush solution designed for use during the transitions from normothermic to mild hypothermic conditions to rinse culture media and native fluids from tissue and whole organ systems prior to suspension in a preservation solution. The company?s CryoStor series of products consist of CryoStor CS2, CryoStor CS5, and CryoStor CS10, which are cryopreservation freeze media products designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing. Its BloodStor products comprise BloodStor 5
|Shares Outstanding||EPS||-0.51||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||23.84%||Sales Growth - Q/Q||-10.12%||P/E||-4.47|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-24.33%||ROE||-34.04%||ROI|
|Current Ratio||7.49||Quick Ratio||6.64||Long Term Debt/Equity||Debt Ratio||0.14|
|Gross Margin||53.57%||Operating Margin||-69.82%||Net Profit Margin||-65.57%||Dividend Payout Ratio|
|Cash From Financing Activities||20 K||Cash From Investing Activities||1.72 M||Cash From Operating Activities||-1.31 M||Gross Profit||880 K|
|Net Profit||-1.03 M||Operating Profit||-1.16 M||Total Assets||15.16 M||Total Current Assets||10.96 M|
|Total Current Liabilities||1.46 M||Total Debt||Total Liabilities||4.32 M||Total Revenue||1.5 M|
|High 52 week||21.26||Low 52 week||9.5||Last close||16.17||Last change||-0.12%|
|RSI||36.44||Average true range||1.01||Beta||0.28||Volume||54.9 K|
|Simple moving average 20 days||-5.7%||Simple moving average 50 days||-12.9%||Simple moving average 200 days||-6.41%|
|Performance Week||4.19%||Performance Month||-21.54%||Performance Quart||-2.82%||Performance Half||-5.49%|
|Performance Year||25.45%||Performance Year-to-date||34.41%||Volatility daily||3.71%||Volatility weekly||8.31%|
|Volatility monthly||17.02%||Volatility yearly||58.96%||Relative Volume||505.82%||Average Volume||187.69 K|
|New High||New Low|
2020-05-18 16:15:00 | BioLife Solutions Promotes Marcus Schulz to Vice President, Global Sales
2020-05-14 20:30:57 | Biolife Solutions Inc BLFS Q1 2020 Earnings Call Transcript
2020-05-14 16:05:00 | BioLife Solutions Announces First Quarter 2020 Financial Results
2020-05-13 12:52:04 | CytoDyn CYDY to Report Q4 Earnings: What's in the Cards?
2020-05-13 10:20:02 | Why Earnings Season Could Be Great for BioLife Solutions BLFS
2020-05-01 08:00:00 | BioLife Solutions Announces Preliminary First Quarter 2020 Revenue
2020-04-20 06:44:21 | Is BioLife Solutions, Inc. NASDAQ:BLFS A Volatile Stock?
2020-03-30 18:35:04 | Edited Transcript of BLFS earnings conference call or presentation 11-Mar-20 8:30pm GMT
2020-03-14 08:58:46 | Did You Miss BioLife Solutions's NASDAQ:BLFS Whopping 428% Share Price Gain?
2020-03-11 16:29:00 | BioLife Solutions Announces Fourth Quarter and Full Year 2019 Financial Results
2020-03-11 14:30:00 | BioLife Solutions, Inc. to Host Earnings Call
2020-02-17 06:14:39 | What Does BioLife Solutions, Inc.'s NASDAQ:BLFS Share Price Indicate?
2020-02-07 07:46:02 | Analysts Back a Turnaround at BioLife Solutions
2020-01-22 05:46:37 | Here's Why We Think BioLife Solutions NASDAQ:BLFS Is Well Worth Watching
2019-12-30 11:35:43 | How Much Did BioLife Solutions, Inc.'s NASDAQ:BLFS CEO Pocket Last Year?
2019-12-26 20:13:18 | What could you have made by investing $1,000 in these Washington companies a decade ago?
2019-12-19 21:26:02 | Smart Money Dumping BioLife Solutions, Inc. BLFS
2019-12-04 06:58:46 | Can BioLife Solutions, Inc. NASDAQ:BLFS Maintain Its Strong Returns?
2019-11-22 03:01:00 | Seattle has potential as a biotech hub, but more companies must stay here and grow
2019-11-21 07:49:34 | Edited Transcript of BLFS earnings conference call or presentation 12-Nov-19 9:30pm GMT
2019-11-12 16:03:00 | BioLife Solutions Acquires Custom Biogenic Systems
2019-11-12 16:01:00 | BioLife Solutions Announces Third Quarter 2019 Financial Results
2019-11-11 08:07:29 | Is BioLife Solutions, Inc. NASDAQ:BLFS Creating Value For Shareholders?
2019-11-07 18:15:55 | BioLife Solutions, Inc. BLFS: Hedge Fund Interest Cooling Off
2019-10-22 09:13:01 | Medical Products Industry Outlook: Prospects Seem Promising
2019-10-14 09:41:00 | A Quick Look at 2 Positive Looking Biotech Plays
2019-09-24 08:00:00 | BioLife Solutions Announces Cell and Gene Therapy Bioproduction Innovation Accelerator
2019-09-24 08:00:00 | iVexSol Announces $2M in Seed Funding
2019-09-16 08:00:00 | BioLife Solutions Announces New evo® Cold Chain Customers
2019-09-11 22:15:02 | Biolife Solutions Inc BLFS President & CEO Michael Rice Sold $553,992 of Shares
2019-09-06 22:15:02 | Biolife Solutions Inc BLFS CFO Greef Roderick De Sold $593,400 of Shares
2019-08-28 08:00:00 | BioLife Solutions Strengthens Sales Team with Key Leadership Additions
2019-08-12 08:00:00 | BioLife Solutions to Attend and Present at Upcoming Scientific and Investor Conferences
2019-08-10 21:12:13 | Edited Transcript of BLFS earnings conference call or presentation 8-Aug-19 8:30pm GMT
2019-08-08 23:23:47 | Biolife Solutions Inc BLFS Q2 2019 Earnings Call Transcript
2019-08-08 16:05:00 | BioLife Solutions Announces Second Quarter 2019 Financial Results
2019-08-08 08:05:00 | BioLife Solutions Completes Acquisition of SAVSU Technologies
2019-08-02 22:15:03 | Biolife Solutions Inc BLFS CFO Greef Roderick De Sold $568,800 of Shares
2019-08-01 10:33:02 | BioLife Solutions BLFS Expected to Beat Earnings Estimates: Can the Stock Move Higher?